MetaCap

Definium Therapeutics Insider Trades

NASDAQ: DFTXHealth Care Medicinal Chemicals and Botanical Products USD

36.90+2.72 (+7.96%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

Last 12 months

Purchases
0 · $0
Sales
14 · $6.44M
Shares bought / sold
0 / 183.23K
Net activity
Net selling $6.4 million

Definium Therapeutics insider activity

Over the last 12 months, Definium Therapeutics insiders reported 41 transactions on SEC Form 4: 0 open-market purchases and 14 sales. Insiders bought $0 and sold $6.4 million worth of stock, for net insider selling of $6.4 million. The largest seller was Barrow Robert, with $3.6 million in reported sales.

The most recent filing shows Karlin Daniel (Chief Medical Officer) selling 10,853 shares at $36.57 on Sep 25, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put DFTX's ownership changes in context.

Summary generated from market data by MetaCap's automated system. Methodology

DFTX insider transactions

Definium Therapeutics insider transactions
DateInsiderTypeSharesValueFiling
Sep 25, 2026Roberts BrandiChief Financial OfficerSale3,377$123.50KForm 4
Sep 25, 2026Wiley Matthew T.Chief Commercial OfficerSale3,097$113.26KForm 4
Sep 25, 2026Barrow RobertChief Executive OfficerSale31,550$1.15MForm 4
Sep 25, 2026Sullivan MarkChief Legal OfficerSale14,051$513.85KForm 4
Sep 25, 2026Karlin DanielChief Medical OfficerSale10,853$396.89KForm 4
Sep 18, 2026Krebs AndreasDirectorOption exercise1,629$57.86KForm 4
Sep 18, 2026Vallone Carol ADirectorOption exercise1,086$38.57KForm 4
Sep 14, 2026Barrow RobertChief Executive OfficerAward750,000—Form 4
Sep 14, 2026Roberts BrandiChief Financial OfficerAward125,000—Form 4
Sep 14, 2026Sullivan MarkChief Legal OfficerAward125,000—Form 4
Sep 14, 2026Wiley Matthew T.Chief Commercial OfficerAward125,000—Form 4
Sep 14, 2026Karlin DanielChief Medical OfficerAward200,000—Form 4
Sep 3, 2026Barrow RobertChief Executive OfficerSale19,023$721.73KForm 4
Sep 2, 2026Barrow RobertChief Executive OfficerAward40,000—Form 4
Aug 12, 2026Wiley Matthew T.Chief Commercial OfficerAward62,500—Form 4
Aug 12, 2026Sullivan MarkChief Legal OfficerAward62,500—Form 4
Aug 12, 2026Karlin DanielChief Medical OfficerAward100,000—Form 4
Aug 12, 2026Roberts BrandiChief Financial OfficerAward62,500—Form 4
Aug 12, 2026Barrow RobertChief Executive OfficerAward375,000—Form 4
Jun 25, 2026Wiley Matthew T.Chief Commercial OfficerSale2,867$129.10KForm 4
Jun 25, 2026Barrow RobertChief Executive OfficerSale29,208$1.32MForm 4
Jun 25, 2026Roberts BrandiChief Financial OfficerSale3,013$135.68KForm 4
Jun 25, 2026Sullivan MarkChief Legal OfficerSale13,008$585.75KForm 4
Jun 25, 2026Karlin DanielChief Medical OfficerSale10,035$451.88KForm 4
Jun 22, 2026Karlin DanielChief Medical OfficerAward100,000—Form 4
Jun 22, 2026Sullivan MarkChief Legal OfficerAward62,500—Form 4
Jun 22, 2026Roberts BrandiChief Financial OfficerAward62,500—Form 4
Jun 22, 2026Barrow RobertChief Executive OfficerAward375,000—Form 4
Jun 22, 2026Wiley Matthew T.Chief Commercial OfficerAward62,500—Form 4
Jun 11, 2026Bruhn Suzanne LouiseDirectorAward4,666—Form 4
Jun 11, 2026Adsett RogerDirectorAward3,555—Form 4
Jun 11, 2026Vallone Carol ADirectorAward4,666—Form 4
Jun 11, 2026GRYSKA DAVID WDirectorAward4,666—Form 4
Jun 11, 2026Krebs AndreasDirectorAward4,666—Form 4
Jun 11, 2026CRYSTAL ROGERDirectorAward4,666—Form 4
Mar 25, 2026Karlin DanielChief Medical OfficerSale8,018$148.09KForm 4
Mar 25, 2026Barrow RobertChief Executive OfficerSale24,431$451.24KForm 4
Mar 25, 2026Sullivan MarkChief Legal OfficerSale10,702$197.67KForm 4
Feb 3, 2026Sullivan MarkChief Legal OfficerAward125,000—Form 4
Feb 3, 2026Roberts BrandiChief Financial OfficerAward150,000—Form 4
Feb 3, 2026Wiley Matthew T.Chief Commercial OfficerAward115,000—Form 4

Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4

Related